Deepa Prasad Sells 3,806 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad sold 3,806 shares of Design Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $6.27, for a total transaction of $23,863.62. Following the completion of the sale, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $125,400. This trade represents a 15.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Design Therapeutics Price Performance

DSGN stock opened at $5.99 on Friday. The company has a market cap of $339.16 million, a P/E ratio of -7.05 and a beta of 1.86. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77. The stock’s fifty day moving average price is $5.88 and its 200-day moving average price is $4.97.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. lifted its stake in shares of Design Therapeutics by 58.3% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock worth $10,182,000 after purchasing an additional 697,368 shares during the period. Baker BROS. Advisors LP raised its position in Design Therapeutics by 2.9% in the third quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company’s stock worth $9,381,000 after acquiring an additional 48,431 shares during the period. Point72 Asset Management L.P. raised its position in Design Therapeutics by 61.6% in the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock worth $8,612,000 after acquiring an additional 609,939 shares during the period. Almitas Capital LLC boosted its stake in shares of Design Therapeutics by 22.1% during the 2nd quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock worth $4,198,000 after acquiring an additional 227,180 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Design Therapeutics by 922.8% in the 3rd quarter. FMR LLC now owns 828,665 shares of the company’s stock worth $4,458,000 after purchasing an additional 747,649 shares in the last quarter. 56.64% of the stock is owned by hedge funds and other institutional investors.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.